Literature DB >> 7909971

The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors.

M Conrad1, D Goldstein, T Andresson, R Schlegel.   

Abstract

The transforming activity of the prototype E5 protein of bovine papillomavirus type 1 (BPV-1) is associated with its binding to, and activation of, both the platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. The E5 proteins of human papillomavirus types 6 and 16 (HPV-6, HPV-16) also transform rodent cells in the presence of the EGF receptor. In this study we examined whether epitope-tagged HPV E5 proteins could associate with three different tyrosine kinase-containing growth factor receptors: the EGF receptor, the erbB2 receptor, and the PDGF receptor. The HPV-6 E5 protein was found to associate efficiently with all three of these growth factor receptors, while the HPV-16 E5 protein did not. These findings suggest either that the in vitro transforming activities of HPV-6 and HPV-16 E5 proteins involve a similar mechanism unrelated to receptor binding (e.g., binding to the 16-kDa membrane pore protein) or that they proceed along distinct pathways, with receptor binding being important for HPV-6. Regardless of the ultimate mechanisms, the differences between the HPV-6 and HPV-16 E5 proteins in binding to growth factor receptors may potentially contribute to the distinctive morphologies of their respective neoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909971     DOI: 10.1006/viro.1994.1244

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion.

Authors:  Lulin Hu; Kendra Plafker; Valeriya Vorozhko; Rosemary E Zuna; Marie H Hanigan; Gary J Gorbsky; Scott M Plafker; Peter C Angeletti; Brian P Ceresa
Journal:  Virology       Date:  2008-11-28       Impact factor: 3.616

3.  Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes.

Authors:  Y P Tsao; L Y Li; T C Tsai; S L Chen
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Cooperative transformation and coexpression of bovine papillomavirus type 1 E5 and E7 proteins.

Authors:  J Bohl; B Hull; S B Vande Pol
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  The regulation mechanism of c-jun and junB by human papillomavirus type 16 E5 oncoprotein.

Authors:  S L Chen; C H Huang; T C Tsai; K Y Lu; Y P Tsao
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Mutational analysis of human papillomavirus type 11 E5a oncoprotein.

Authors:  S L Chen; T Z Tsai; C P Han; Y P Tsao
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion.

Authors:  Lulin Hu; Brian P Ceresa
Journal:  Virology       Date:  2009-08-26       Impact factor: 3.616

8.  Bap31 is a novel target of the human papillomavirus E5 protein.

Authors:  Jennifer A Regan; Laimonis A Laimins
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

9.  Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line.

Authors:  I Oelze; J Kartenbeck; K Crusius; A Alonso
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.

Authors:  Jiafen Hu; Ricai Han; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.